Polysaccharides (e.g., Cellulose, Etc.) Patents (Class 424/488)
  • Patent number: 11786457
    Abstract: The invention provides methods and compositions for reducing tumor-mediated immune evasion and inducing patient-specific immunization.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: October 17, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: Sandeep T. Koshy, David J. Mooney
  • Patent number: 11779686
    Abstract: A medical device substrate with a coating including a functional layer located on the substrate, with the functional layer including at least one sugar alcohol and being bonded to the substrate directly or indirectly via a functionalization of the sugar alcohol. Alternatively, the functional layer may also include other saccharides, in which case it is essential that polymerization of the saccharides takes place only upon bonding to the substrate. The inventive medical device exhibits reduced platelet adhesion and aggregation.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: October 10, 2023
    Assignee: Phenox GmbH
    Inventors: Uwe Schedler, Christian Heise, Thomas Thiele, Hans Henkes, Hermann Monstadt, Ralf Hannes, Tim Lenz-Habijan, Catrin Bannewitz
  • Patent number: 11759470
    Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: September 19, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Akitsuna Akagi, Kai Suzuki, Atsuya Nakamura, Toru Nishibayashi
  • Patent number: 11752099
    Abstract: The present disclosure is directed to injectable formulations that include biodegradable polymers based on trimethylene carbonate (TMC) with mole fractions of polylactic acid (PLA) and/or polyglycolic acid (PGA) that are used to deliver a bioactive agent to a targeted site. Excipients such as polyethylene glycol (PEG) may be added to the formulations to reduce the injection force and/or to modulate the release of the bioactive agent. Suitable biodegradable polymers for use in the injectable formulations include D,L-PLA:TMC, D-PLA:TMC, L-PLA:TMC, TMC:PLA:PGA and variations thereof. Additionally, copolymers of TMC and PLA and terpolymers of TMC:PLA:PGA may be formed into nanoparticles and delivered to the target site with an injectable crosslinkable polyethylene glycol system. In at least one embodiment, the injectable formulations are used to treat ocular diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: September 12, 2023
    Inventors: Paul C. Begovac, Robert L. Cleek, Mei Li
  • Patent number: 11752237
    Abstract: A method for forming a bioactive agent spatially patterned includes providing a photocrosslinkable hydrogel that includes a photocrosslinkable base polymer, photocrosslinkable bioactive agent coupling polymer macromers, and at least one bioactive agent that couples to the photocrosslinkable bioactive agent coupling polymer macromer, an selectively exposing discrete portions of the photocrosslinkable hydrogel to actinic radiation effective to initiate cross-linking of the base polymer and the bioactive agent coupling polymer macromers at the exposed portions.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: September 12, 2023
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Eben Alsberg, Oju Jeon
  • Patent number: 11690814
    Abstract: Provided is a composition comprising suplatast tosilate or pharmaceutically acceptable derivatives thereof for use in a method of treating cough associated with interstitial lung disease, such as cough associated with pulmonary fibrosis.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: July 4, 2023
    Assignee: CONRIG PHARMA APS
    Inventors: John Bondo Hansen, Mikael S. Thomsen, Niels Skjærbæk
  • Patent number: 11642440
    Abstract: Various aspects described herein relate to compositions comprising silk fibroin particles and methods of using the same, as well as devices and methods of delivering such compositions. The compositions described herein are suitable for injection into a site of defect in a soft tissue to provide bulking and/or augmentation effect to the soft tissue.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: May 9, 2023
    Assignee: Sofregen Medical, Inc.
    Inventors: Anh Hoang-Lindsay, Christopher P. Gulka, Jodie E. M. Giordano, Joseph E. Brown, Thomas L. Carroll
  • Patent number: 11623019
    Abstract: Various aspects described herein relate to compositions comprising silk fibroin particles and methods of using the same, as well as devices and methods of delivering such compositions. The compositions described herein are suitable for injection into a site of defect in a soft tissue to provide bulking and/or augmentation effect to the soft tissue.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: April 11, 2023
    Assignee: Sofregen Medical, Inc.
    Inventors: Anh Hoang-Lindsay, Christopher P. Gulka, Jodie E. M. Giordano, Joseph E. Brown, Thomas L. Carroll
  • Patent number: 11529357
    Abstract: An injectable pharmaceutical composition comprising carbamazepine and sulfobutylether-7-?-cyclodextrin, wherein said composition is essentially free of 10-Br-carbamazepine, is disclosed. Methods for the manufacture of said composition and methods for treatment of disease using said composition are also disclosed.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: December 20, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Hans Petersen, Jesper Tungelund Larsen
  • Patent number: 11446305
    Abstract: The present disclosure relates to relates to improved dietary supplement compositions formulated in a therapeutic effective amount for enhancing play of electronic video games. Specifically, the present disclosure relates to compositions for oral consumption, in the form of dietary supplements, foods or beverages, which provide fast acting, broad spectrum cognitive enhancing formulas for gaming and video game purposes. The formulas consist of ingredients for enhancing certain parameters to improve gaming abilities, including increased energy and alertness, brain wave function, neurotransmission, reduced stress, improved sleep, improved eye health, improved blood flow, and improved hydration and reduced muscle soreness.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: September 20, 2022
    Assignee: NutriScience Innovations LLC
    Inventor: Michael Lelah
  • Patent number: 11446244
    Abstract: Disclosed are pharmaceutical formulations and methods using Verteporfin Ribavirin and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions.
    Type: Grant
    Filed: January 17, 2021
    Date of Patent: September 20, 2022
    Inventor: Matthew McLeay
  • Patent number: 11419941
    Abstract: The vaginal hydrogel may be a composition which includes a glycosaminoglycan, a reactive molecule, and, in some embodiments, a therapeutic agent. The glycosaminoglycan and the reactive molecule may include either thiol groups or thiol reactive sites and have a pH that is within a range of a normal vaginal environment. Some of the thiol groups may interact with the vaginal mucosa and allow the hydrogel to remain in the vagina for a longer period than existing compounds intended for intravaginal administration. Therapeutic agents may be included in the composition. In these embodiments, the hydrogel acts as a vehicle which delivers the therapeutic agent.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: August 23, 2022
    Inventor: Brenda K. Mann
  • Patent number: 11413251
    Abstract: The present invention relates to a gelatin product comprising a core component, wherein the core component is encased partially or fully by a gelatin gel. The gelatin gel is produced from a homogeneous casting compound containing the following constituents dissolved in water: 3 to 20 wt % of gelatin having a mean molecular weight, determined by gel chromatography, of at least 130 kDa, wherein the proportion of the molecular weight fraction above 100 kDa is at least 35 wt %; up to 60 wt % of glucose syrup with a viscosity of less than 1000 mPa·s, measured with a dry matter content of 80 wt % and at a temperature of 60° C.; and up to 60 wt % of sucrose, wherein the casting compound comprises a dry matter content of at least 70 wt %.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: August 16, 2022
    Assignees: GELITA AG, WINKLER UND DÜNNEBIER SÜSSWARENMASCHINEN GMBH
    Inventors: Eberhard Dick, Sarah Engelhardt, Johanna Schmidgall, Holger Brack, Andre Weins
  • Patent number: 11406596
    Abstract: A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: August 9, 2022
    Assignee: NICOX OPHTHALMICS, INC.
    Inventors: Jean-Michel Bukowski, Akshay Nadkarni, José L. Boyer, Brigitte Duquesroix-Chakroun, Tomas Navratil
  • Patent number: 11331316
    Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 17, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventor: Peng Li
  • Patent number: 11311536
    Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 26, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventor: Peng Li
  • Patent number: 11311490
    Abstract: A pharmaceutical pellet is disclosed, comprising a spherical core containing active ingredient with a smooth surface and a coating on the core which controls the release of the active ingredient in a pH-independent manner. With such a pellet the release of the active ingredient can follow a profile with a lag phase of 60 minutes to 840 minutes, a proportion of 5 wt. % or less of the active ingredient being released during the lag phase. The active ingredient can furthermore be released from the pellet with a profile such that after the lag phase the release of the active ingredient amounts to between 3 and 25 wt. % per hour.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: April 26, 2022
    Assignee: ADD ADVANCED DRUG DELIVERY TECHNOLOGIES LTD.
    Inventors: Burkhard Schlutermann, Manfred Kohlmeyer
  • Patent number: 11248094
    Abstract: The present invention relates to methods of providing biocompatible/biodegradable hydrogels obtained by crosslinking of biopolymers (for example polysaccharides or proteins) in the semi-solid (modelling-clay like) state at water content below 70% by weight. The resulting materials can be applied in medicine, pharmacy and/or in cosmetics.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 15, 2022
    Assignee: SOLYPLUS GMBH
    Inventors: Richard Dolph Andersen, Annette Assogba-Zandt, Elena Maltseva, Andreas Voigt
  • Patent number: 11229586
    Abstract: A surfactant-free cosmetic composition is disclosed. The composition is a stable water in silicone oil (W/S) formulation containing a silicone oil phase portion and an aqueous phase portion, wherein the silicone oil phase portion contains an emollient having a pyrrolidone carboxylic acid group, oil-absorbing powder and silicone oil, and the aqueous phase portion contains 50 wt.% or more of water based on the total weight of the surfactant-free cosmetic composition. The composition may further contain a high content of vitamin C or a vitamin C derivative and has improved long term storage stability.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: January 25, 2022
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Seong Chan Eo, Seung Han Park, Byung Fhy Suh, Ji Sik Shin, Dong Won Choi, Byung Guen Chae
  • Patent number: 11219703
    Abstract: The invention relates to a scaffold material comprising a plurality of particles of a highly porous polymeric material, characterized in that said scaffold material becomes a shapeable paste once hydrated. The specific features of the particle material impart a special behavior to the scaffold, which can be easily shaped and even highly reversibly compressed, so that in certain aspects it can, if needed, be injected, said capacity to be shaped being maintained over a high range of hydration conditions. A particular aspect of the invention relates, therefore, to the use of such scaffold material for the manufacturing of shapeable body implants, such as breast implants, to the shapeable body implants themselves as well as to non-invasive methods for using thereof in creating or reconstructing a three-dimensional volume in a subject's body part.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: January 11, 2022
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Amélie Barbara Hildegarde Béduer, Thomas Braschler, Philippe Renaud, Giorgio Pietramaggiori, Saja Scherer
  • Patent number: 11214656
    Abstract: A preparation method of a cross-linked sodium hyaluronate gel is disclosed, which including: preparing an alkaline aqueous solution of hyaluronic acid: formulating a sodium hyaluronate alkali liquor with the concentration of 10-30% g/ml; and carrying out a cross-linking reaction: the cross-linking agent used in the cross-linking reaction being divinyl sulfone or 1,4-butanediol diglycidyl ether, the cross-linking reaction being carried out in an alkaline aqueous solution of hyaluronic acid, the reaction temperature of the cross-linking reaction being 20-40° C., the time of the cross-linking reaction being 4-8 h, and the like. The method of this invention has many advantages, such as easily available raw materials, mild reaction conditions, high cross-linking efficiency, simple process and post-treatment, and easy operation.
    Type: Grant
    Filed: December 29, 2019
    Date of Patent: January 4, 2022
    Assignees: Hangzhou Singclean Medical Products Co., Ltd, Zhejiang University of Science and Technology
    Inventors: Zhiguo Zhang, Yange Suo, Wei Huang, Weiqing Sun
  • Patent number: 11202755
    Abstract: By individually metering and dispensing specific volumes and/or weights of each component of a dosage, an amount of the components for each dose is secured with very high accuracy. A method for dosing a pharmaceutical product in a sealed container, such as, for example, a packet, sachet, blister pack, or other unit dose form. The dosage may include a first component that is a thickening agent and a second component that is an active ingredient. The thickening agent serves as a carrier that allows the active ingredient to dissolve in the mouth and be swallowed without the administration of water. The method includes providing the first component by measuring the volume or weighing the mass of the first component and measuring the volume or weighing the mass of the second component. Subsequent components may also be individually measured or weighed before being added to a package.
    Type: Grant
    Filed: February 21, 2016
    Date of Patent: December 21, 2021
    Assignee: UniWell Laboratories, LLC
    Inventors: Alan Jones, Cesar Rodriguez, David Henzler, Jeff Currington, Megha Sharma, Daniel Aldrich, Cameron Currington, Michael Sloane
  • Patent number: 11179392
    Abstract: The present invention provides a solid pharmaceutical formulation of PARP inhibitors and its use thereof, and more specifically a solid dispersion powder including 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione and polymers, wherein the content of polymers is from about 50 wt % to about 80 wt %, and wherein less than 10 wt % of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione is in crystalline form. The present invention also provides a method for preparing the solid dispersion powder, a pharmaceutical composition including the solid dispersion powder and the use of the pharmaceutical composition for treating diseases caused by PARP activity abnormalities.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: November 23, 2021
    Assignee: IMPACT THERAPEUTICS, INC.
    Inventors: Suixiong Cai, Yushen Guo
  • Patent number: 11179505
    Abstract: Methods for producing crosslinked tissue matrices, crosslinked tissue matrices produced by such methods, as well as tissue products comprising such tissue matrices are disclosed. The methods comprise (1) dehydrating a collagen-containing tissue matrix to form a dehydrated collagen-containing tissue matrix; and (2) irradiating the dehydrated collagen-containing tissue matrix such that at least a portion of the dehydrated collagen-containing tissue matrix is crosslinked.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: November 23, 2021
    Assignee: LifeCell Corporation
    Inventors: Israel Jessop, Ming F. Pomerleau, Nathaniel Bachrach
  • Patent number: 11160271
    Abstract: Disclosed are an anti-freezing agent for protecting a biological tissue from being damaged during a freezing treatment and a preparation method therefor. The method for preparing the anti-freezing agent involves mixing ethylene glycol, water and dimethylsulfoxide homogeneously to form a matrix, and then slowly adding sodium polyacrylate. The prepared anti-freezing agent is coated onto biological tissue during a freezing treatment such that damage to the biological tissue is reduced.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: November 2, 2021
    Assignee: TAIPEI VETERANS GENERAL HOSPITAL
    Inventors: Po Kuei Wu, Wei Ming Chen, Cheng Fong Chen, Jir You Wang, Wen Hai Wu
  • Patent number: 11142846
    Abstract: A continuous wire drive system for a needleless electrospinning apparatus, the electrospinning apparatus including an electrospinning enclosure and within which a nanoscale or submicron scale polymer fiber web is formed onto a substrate from a liquid polymer layer coated onto a plurality of continuous electrode wires passing through the electrospinning enclosure. The continuous wire drive system includes a master wire drive drum and a slave wire drive drum, each of the master wire drive drum and slave wire drive drum including a plurality of wire guides, each of the wire guides including a channel or groove for receiving one of the plurality of continuous electrode wires. The continuous wire drive system is external to the electrospinning apparatus, and the continuous wire drive system drives the plurality of continuous electrode wires through the electrospinning enclosure.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: October 12, 2021
    Assignee: SHPP GLOBAL TECHNOLOGIES B.V.
    Inventors: Xuezhi Jin, Richard Peters, Evelyn Pearson
  • Patent number: 11135315
    Abstract: A staining composition for use in making biofilm detectable on viable tissue wherein the composition preferentially stains the biofilm and comprises a staining agent in a quantity effective to stain the biofilm and render it detectable.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: October 5, 2021
    Assignee: CONVATEC TECHNOLOGIES INC.
    Inventors: Phillip Godfrey Bowler, Daniel Gary Metcalf, David Parsons, Emily Sonia Johnson
  • Patent number: 11123452
    Abstract: The present invention relates to an alkyl chitosan-graphene oxide composite sponge and preparation method and application thereof. The alkyl chitosan-graphene oxide composite sponge provided by the present invention includes alkyl chitosan and graphene oxide absorbed on the alkyl chitosan, and the adsorbing capacity of the graphene oxide is 3-28 wt. %. In the present invention, alkyl chitosan is used as a matrix to combine graphene oxide and alkyl chitosan; the obtained composite sponge has excellent hemostatic performance and blood absorption capacity. Results of embodiments indicate that the in-vitro whole blood coagulation time is less than 58 s, the hemostasis time of a rabbit femoral artery hemorrhage model is less than 155 s, the hemorrhage mass is less than 5.4 g, and the hemostatic effect is superior to a pure alkyl chitosan sponge or graphene oxide powder when the composite sponge provided by the present invention is used for hemostasis.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: September 21, 2021
    Assignee: Institute of Medical Support Technology, Academy of System Engineering, Academy of Military Science
    Inventors: Jing Guan, Jian Yang, Ying Zhang, Feng Tian, Jimin Wu, Sheng Ding, Zhihong Li, Chunlai Wang
  • Patent number: 11103601
    Abstract: Disclosed is a lymph targeting nuclear magnetic contrast agent using a brown algae polysaccharide as a carrier, and a preparation method and a use thereof. A macromolecular contrast agent with good water solubility was prepared by using the brown algae polysaccharide as the carrier, using mannose or mannose derivatives as a mannose receptor (MBP) recognition group, and using a paramagnetic metal ion chelate as a nuclear magnetic resonance imaging group. The binding capacity of lymphoid tissue was improved. The mannose or mannose derivative group introduced into the synthesized contrast agent molecule achieves the goal of binding to the enriched mannose receptors in the lymphoid tissues. At the same time, after the contrast agent is injected subcutaneously, both lymph vessels and lymph nodes were clearly visualized under MRI scanning.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: August 31, 2021
    Assignee: OCEAN UNIVERSITY OF CHINA
    Inventors: Tao Jiang, Shengbiao Wan, Wei Shang, Nan Zhang, Mingliang Zhao
  • Patent number: 11096412
    Abstract: A nicotine pouch composition is disclosed, the pouch composition comprising free-base nicotine and having a water content of at least 15% by weight of said pouch composition. Furthermore, an oral nicotine pouch product comprising the pouch composition and a method for manufacturing the oral nicotine pouch product is disclosed.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: August 24, 2021
    Inventors: My Ly Lao Stahl, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen, Bine Hare Jakobsen
  • Patent number: 11083684
    Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions made with a di-amine or multiamine crosslinker in the presence of a carbodiimide coupling agent.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: August 10, 2021
    Assignee: ALLERGAN INDUSTRIE, SAS
    Inventors: Gabriel N. Njikang, Xiaojie Yu, Futian Liu, Nicholas J. Manesis
  • Patent number: 11061033
    Abstract: A Fe(II)- and Ca+2-chelated alginate/gelatin conjugate.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: July 13, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Abhinav Acharya, Steven R. Little, Tatum V. Tarin
  • Patent number: 11040066
    Abstract: The present disclosure relates to topical compositions comprising water, solvent, thickener, preservative and conditioning agent wherein the composition has a viscosity approximately in the range 200-6000 cP at 25° C. following exposure to gamma radiation, to use of the composition in a dressing and the use of compositions and dressings in treatment or prophylaxis of burns.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: June 22, 2021
    Assignee: Safeguard Medical Holdco, LLC
    Inventor: Mark Lait
  • Patent number: 11006659
    Abstract: A fortified date fruit product includes date fruit sugar and one or more mineral phosphate nanostructures. The mineral phosphate nanostructures can be selected from one or more of calcium phosphate, zinc phosphate, and iron phosphate nanostructures, among others. The mineral phosphate nanostructures can have a particle size ranging from about 5 nm to about 100 nm, e.g., about 5 nm to about 20 nm, about 50 nm to about 100 nm, and about 75 nm to about 100 nm.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: May 18, 2021
    Assignee: KING SAUD UNIVERSITY
    Inventors: Ali Abdullah Alshatwi, Jegan Athinarayanan, Periasamy Vaiyapuri Subbarayan
  • Patent number: 11000626
    Abstract: Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin C derivatives. The compositions provide for extended release of active vitamin C into tissue, promoting collagenesis and other benefits to skin.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: May 11, 2021
    Assignee: ALLERGAN INDUSTRIE, SAS
    Inventors: Futian Liu, Xiaojie Yu, Jessamine P. Winer-Jones, Nicholas J. Manesis, Hengli Liu, Gabriel Njikang, Athene Wan Chie Chan
  • Patent number: 10994013
    Abstract: Provided is a dosage form for delivery of a therapeutic agent comprising a polymer matrix comprising arabinogalactan and a therapeutic agent uniformly dispersed in said polymer matrix. In some embodiments, the dosage form is selected from the group consisting of a microsphere, a nanosphere, a powder, a tablet, a film or a pellet enclosed in a capsule. Also provided are methods for preparing the dosage form.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: May 4, 2021
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Kalpana N. Thakare, David B. Lebo
  • Patent number: 10980887
    Abstract: The present invention relates to a method for providing an embedded mammalian cell, comprising the steps of providing an alginate sulfate in aqueous solution; reacting the alginate sulfate to form a hydrogel in a gelation step, providing a precursor cell, and embedding the precursor cell in the sulfated alginate hydrogel in an embedding step, thus yielding an sulfated alginate hydrogel embedded cell. The invention further relates to sulfated alginate hydrogels, and cellular grafts comprising a mammalian cell embedded in sulfated alginate hydrogel.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: April 20, 2021
    Assignee: ETH ZURICH
    Inventors: Marcy Zenobi-Wong, Gemma Palazzolo, Rami Mhanna, Jana Becher, Stefanie Moller, Matthias Schnabelrauch
  • Patent number: 10973760
    Abstract: Instantly dissolving buccal films comprising certain pH modifiers, film formers, film modifiers, and solubilizing agents are provided. Methods of providing the buccal film to enhance the dissolution and bioavailability of low solubility basic drugs, such as dapoxetine hydrochloride, in a subject are also provided.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: April 13, 2021
    Assignee: King Abdulaziz University
    Inventors: Shaimaa M. Badr-Eldin, Hibah M. Aldawsari, Abdelsattar Omar
  • Patent number: 10967097
    Abstract: A novel hydrogel wound dressing therapy and methods for making the same. The novel methods comprise forming two biopolymers, chitosan and hyaluronic acid, together into a wound dressing with inherent ability to enhance wound closure. The novel composition of the subject invention comprises cross-linked chitosan/hyaluronic acid hydrogels manufactured according to the methods disclosed having a specific cross-link density that results in a swelling ratio of 20 to 100. Hydrogels manufactured in accordance with the method of the invention dramatically increase healing rates and greatly improves outcomes of wound injuries.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: April 6, 2021
    Assignee: Oceanit Laboratories, Inc
    Inventors: Jacob Pollock, Joanne S. M. Ebesu, Dexter Poon
  • Patent number: 10959990
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions comprise aceclidine hydrochloride, polysorbate 80, mannitol, anhydrous hypromellose, disodium edetate dihydrate, benzalkonium chloride, sorbic acid and anhydrous sodium citrate and optionally tropicamide.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: March 30, 2021
    Assignee: PRESBYOPIA THERAPIES, INC
    Inventor: Gerald Horn
  • Patent number: 10918625
    Abstract: The present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, the composition containing a sesquiterpene derivative compound represented by Chemical Formula 1 of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient. Whereas the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects, the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: February 16, 2021
    Assignee: KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
    Inventor: Sangtaek Oh
  • Patent number: 10906992
    Abstract: There is provided a method for producing a low polymerization degree cellulose ether having a less yellowish appearance and having excellent long-term storage stability through depolymerization of a high polymerization degree cellulose ether with an acid and without requiring an additive other than the acid. More specifically, there is provided a method for producing a low polymerization degree cellulose ether, including a step of depolymerizing a high polymerization degree cellulose ether with an acid to obtain a low polymerization degree cellulose ether mixture and a step of neutralizing the acid present in the low polymerization degree cellulose ether mixture, wherein ultraviolet is applied in the step of depolymerizing or between the steps of depolymerizing and neutralizing.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: February 2, 2021
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Taishi Kitaguchi, Akira Kitamura, Shintaro Matsusue, Mitsuhiro Yoshida
  • Patent number: 10905664
    Abstract: The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 2, 2021
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Swati Kulkarni, Bijay Kumar Padhi, Shanvas Alikunju, Rajeev Singh Raghuvanshi, Srinivas Ramchandra Sidgiddi, Anirudh Gautam
  • Patent number: 10850136
    Abstract: A blend for use in a personal care composition comprises a dialkyl amphiphilic component and an ester of a long chain branched fatty acid and a long chain branched alcohol. The blend can be pastillated and/or flaked, and can be used as the oil phase of an oil-in-water emulsion. The blend can be used in a moisturiser composition for moisturising skin.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: December 1, 2020
    Inventors: Graham Timothy Pennick, Michael Andrew Oakley, Bhaven Chavan
  • Patent number: 10815345
    Abstract: The present invention relates to a method for preparing a chitosan-based matrix (4) comprising the following steps: a) two separate chitosan porous layers (1, 2) obtained from lyophilisation of layers of one or more solutions of chitosan are provided, b) the chitosan porous layers of a) are neutralized and washed, c) a face (1a, 2a) of each chitosan porous layer is acidified with an acid, d) a fiber reinforcement member (3) is provided and positioned between the two acidified faces of the two chitosan porous layers, e) the two chitosan porous layers and the fiber reinforcement member are let to dry to obtain a matrix having the fiber reinforcement member embedded therein. The invention also relates to an implant comprising a matrix obtained according to such a method.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: October 27, 2020
    Assignee: SOFRADIM PRODUCTION
    Inventors: Aurelie Serrero, Mylene Desorme
  • Patent number: 10786601
    Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: September 29, 2020
    Assignee: TEOXANE
    Inventors: Francois Bourdon, Stephane Meunier
  • Patent number: 10772901
    Abstract: Provided is a pharmaceutical composition for use in a method of preventing or treating a urinary tract infection (UTI), chronic cystitis, overactive bladder, partial bladder obstruction or urethritis, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, where in said method said composition is administered intraurethrally, intravesically, intraureterally and/or intrarenally, as well as a pharmaceutical composition for use in a method of preventing or treating bladder cancer, where in said method said composition is administered intravesically, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, wherein said tannins are bound to an anti-cancer agent and/or liposomes containing an anti-cancer agent, together with compositions related thereto.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 15, 2020
    Assignees: UroPharma Limited, Synesis LLC
    Inventors: Howard Shapland, Scott Glickman, Christian G. Krueger, Amy B. Howell, Jess D. Reed
  • Patent number: 10744236
    Abstract: The present invention relates to protein biocoacervates and biomaterials vessel graft systems used in cardiovascular applications and other medical applications, the components utilized in the vessel graft systems and the methods of making and using such systems. More specifically the present invention relates to protein biocoacervates and biomaterials vessel graft systems used in various medical applications and/or the devices used in such vessel graft systems including, but not limited to, vessel grafts as drug delivery devices for the controlled release of pharmacologically active agents, tubular grafts, vascular grafts, protein biomaterial sutures and biomeshes, protein biomaterial adhesives and glues, and other biocompatible biocoacervate or biomaterial devices used in the vessel graft systems of the present invention.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: August 18, 2020
    Assignee: PETVIVO HOLDINGS, INC.
    Inventor: David B. Masters
  • Patent number: 10709820
    Abstract: A method for producing a storable molded body made of bacterial cellulose and a molded body produced according to the method. A preferred method includes providing a molded body made of bacterial cellulose. Optionally, mechanically pressing the entire molded body or parts of the molded body at temperatures in the range of 10° C. to 100° C. and pressures in the range of 0.01 to 1 MPa for a pressing time of 10-200 min. Treating the molded body with a solution of 20% by weight to 50% by weight of glycerol and 50% by weight to 80% by weight of a C1-C3-alcohol/water mixture. Drying the treated molded body.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: July 14, 2020
    Assignee: BIOTRONIK AG
    Inventor: Jens Ulmer
  • Patent number: 10709787
    Abstract: The present invention relates to a composition comprising hydrogels from functionalized hyaluronic acid derivatives, said hydrogels loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP) intended for the oral treatment of celiac disease. Specifically, this invention concerns a one-pot methodology useful to prepare methacrylic derivatives of hyaluronic acid, through the formation of a specific active group on hydroxyl groups of hyaluronic acid, the subsequent substitution of the inserted active group with ethylenediamine and finally, the reaction with methacrylic anhydride. The obtained methacrylic hyaluronic acid derivatives are used to prepare hydrogels through irradiation and loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP). The ability of prepared hydrogels to allow the enzyme release, as active form in simulated gastrointestinal fluids is proved.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: July 14, 2020
    Assignee: NEMYSIS LIMITED
    Inventors: Giovanna Pitarresi, Fabio Salvatore Palumbo, Gaetano Giammona